View in EDS HTML Full Text PDF Full Text

Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.

Saved in:
Bibliographic Details
Title: Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.
Authors: Chang E; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim MS; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; ImpriMedKorea, Inc., Seoul, Republic of Korea., Park SY; Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea., Kwon K; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Jang HM; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Lim SY; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Bae S; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Jung J; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim MJ; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Chong YP; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Lee SO; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Choi SH; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim YS; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Choi G; ImpriMedKorea, Inc., Seoul, Republic of Korea., Lim S; ImpriMed, Inc., Mountain View, CA, United States., Koo J; ImpriMedKorea, Inc., Seoul, Republic of Korea.; ImpriMed, Inc., Mountain View, CA, United States.; Department of Chemical Engineering, Hongik University, Seoul, Republic of Korea., Kim SH; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Source: Frontiers in medicine [Front Med (Lausanne)] 2026 Jan 07; Vol. 12, pp. 1734109. Date of Electronic Publication: 2026 Jan 07 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101648047 Publication Model: eCollection Cited Medium: Print ISSN: 2296-858X (Print) Linking ISSN: 2296858X NLM ISO Abbreviation: Front Med (Lausanne) Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41574379
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Chang+E%22">Chang E</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+MS%22">Kim MS</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.; ImpriMedKorea, Inc., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Park+SY%22">Park SY</searchLink>; Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kwon+K%22">Kwon K</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Jang+HM%22">Jang HM</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lim+SY%22">Lim SY</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Bae+S%22">Bae S</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Jung+J%22">Jung J</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+MJ%22">Kim MJ</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Chong+YP%22">Chong YP</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+SO%22">Lee SO</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Choi+SH%22">Choi SH</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+YS%22">Kim YS</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Choi+G%22">Choi G</searchLink>; ImpriMedKorea, Inc., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lim+S%22">Lim S</searchLink>; ImpriMed, Inc., Mountain View, CA, United States.<br /><searchLink fieldCode="AU" term="%22Koo+J%22">Koo J</searchLink>; ImpriMedKorea, Inc., Seoul, Republic of Korea.; ImpriMed, Inc., Mountain View, CA, United States.; Department of Chemical Engineering, Hongik University, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Kim+SH%22">Kim SH</searchLink>; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101648047%22">Frontiers in medicine</searchLink> [Front Med (Lausanne)] 2026 Jan 07; Vol. 12, pp. 1734109. <i>Date of Electronic Publication: </i>2026 Jan 07 (<i>Print Publication: </i>2025).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Media+S%2EA%22">Frontiers Media S.A </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101648047 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2296-858X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222296858X%22">2296858X </searchLink><i>NLM ISO Abbreviation: </i>Front Med (Lausanne) <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41574379
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fmed.2025.1734109
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1734109
    Titles:
      – TitleFull: Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Chang E
      – PersonEntity:
          Name:
            NameFull: Kim MS
      – PersonEntity:
          Name:
            NameFull: Park SY
      – PersonEntity:
          Name:
            NameFull: Kwon K
      – PersonEntity:
          Name:
            NameFull: Jang HM
      – PersonEntity:
          Name:
            NameFull: Lim SY
      – PersonEntity:
          Name:
            NameFull: Bae S
      – PersonEntity:
          Name:
            NameFull: Jung J
      – PersonEntity:
          Name:
            NameFull: Kim MJ
      – PersonEntity:
          Name:
            NameFull: Chong YP
      – PersonEntity:
          Name:
            NameFull: Lee SO
      – PersonEntity:
          Name:
            NameFull: Choi SH
      – PersonEntity:
          Name:
            NameFull: Kim YS
      – PersonEntity:
          Name:
            NameFull: Choi G
      – PersonEntity:
          Name:
            NameFull: Lim S
      – PersonEntity:
          Name:
            NameFull: Koo J
      – PersonEntity:
          Name:
            NameFull: Kim SH
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 01
              Text: 2026 Jan 07
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-print
              Value: 2296-858X
          Numbering:
            – Type: volume
              Value: 12
          Titles:
            – TitleFull: Frontiers in medicine
              Type: main
ResultId 1